Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheson, B. D.
Right arrow Articles by Keating, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheson, B. D.
Right arrow Articles by Keating, M. J.

Journal of Clinical Oncology, Vol 8, 813-819, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

BD Cheson, PA Cassileth, DR Head, CA Schiffer, JM Bennett, CD Bloomfield, R Brunning, RP Gale, MR Grever and MJ Keating
Clinical Investigations Branch, National Cancer Institute, Bethesda, MD 20892.

The National Cancer Institute (NCI) sponsored a workshop to develop a set of standardized diagnostic and response criteria for acute myeloid leukemia (AML) clinical trials. The French-American-British (FAB) classification was retained for diagnosing AML, with the addition of patients with bone marrow morphologic features of a myelodysplastic syndrome and less than 30% bone marrow blasts, but with greater than or equal to 30% blasts in the peripheral blood. In this report, there are four important subgroups of AML not defined in the FAB classification that are discussed: undifferentiated acute leukemia, MO (AML lacking definitive myeloid differentiation by morphology or conventional cytochemistry but with ultrastructural or immunophenotypic evidence for AML), mixed lineage leukemia, and hypocellular AML. Definitions of response for clinical trials are presented to facilitate comparisons among different studies. Complete remission is considered the only response worth reporting in phase III trials, since lesser responses do not improve survival. Partial remissions may be of interest to identify active new agents in phase I and II studies. Monoclonal antibodies and cytogenetic studies are not part of the routine assessment of remission or reassessment at relapse, and their role in the evaluation of patients with AML is currently being evaluated in clinical trials. Although we recognize that some of the definitions in this report are arbitrary, generalized use of these guidelines will make results of clinical trials more comparable and interpretable.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al.
Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Clin. Cancer Res., June 15, 2008; 14(12): 3889 - 3895.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Rizzieri, E. Feldman, J. F. DiPersio, N. Gabrail, W. Stock, R. Strair, V. M. Rivera, M. Albitar, C. L. Bedrosian, and F. J. Giles
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res., May 1, 2008; 14(9): 2756 - 2762.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Wandt, U. Schakel, F. Kroschinsky, G. Prange-Krex, B. Mohr, C. Thiede, U. Pascheberg, S. Soucek, M. Schaich, and G. Ehninger
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients
Blood, February 15, 2008; 111(4): 1855 - 1861.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. J.M. de Jonge, A. C. Weidenaar, A. ter Elst, H. M. Boezen, F. J.G. Scherpen, J. C.A. Bouma-ter Steege, G. J.L. Kaspers, B. F. Goemans, U. Creutzig, M. Zimmermann, et al.
Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia
Clin. Cancer Res., February 1, 2008; 14(3): 924 - 930.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Ades, M. A. Sanz, S. Chevret, P. Montesinos, P. Chevallier, E. Raffoux, E. Vellenga, A. Guerci, A. Pigneux, F. Huguet, et al.
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
Blood, February 1, 2008; 111(3): 1078 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. Montesinos, I. Lorenzo, G. Martin, J. Sanz, M. L. Perez-Sirvent, D. Martinez, G. Orti, L. Algarra, J. Martinez, F. Moscardo, et al.
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Haematologica, January 1, 2008; 93(1): 67 - 74.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. DeAngelo, D. Yu, J. L. Johnson, S. E. Coutre, R. M. Stone, A. T. Stopeck, J. P. Gockerman, B. S. Mitchell, F. R. Appelbaum, and R. A. Larson
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Blood, June 15, 2007; 109(12): 5136 - 5142.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wetzler, B. L. Sanford, J. Kurtzberg, D. DeOliveira, S. R. Frankel, B. L. Powell, J. E. Kolitz, C. D. Bloomfield, and R. A. Larson
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
Blood, May 15, 2007; 109(10): 4164 - 4167.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Lehrnbecher, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and U. Creutzig
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
Blood, February 1, 2007; 109(3): 936 - 943.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al.
Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol., December 20, 2006; 24(36): 5703 - 5710.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Knapper, A. K. Burnett, T. Littlewood, W. J. Kell, S. Agrawal, R. Chopra, R. Clark, M. J. Levis, and D. Small
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Blood, November 15, 2006; 108(10): 3262 - 3270.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Creutzig, M. Zimmermann, T. Lehrnbecher, N. Graf, J. Hermann, C. M. Niemeyer, A. Reiter, J. Ritter, M. Dworzak, J. Stary, et al.
Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98
J. Clin. Oncol., September 20, 2006; 24(27): 4499 - 4506.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. W.L. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli, D. Thomas, W. Wierda, E. Apostolidou, M. Albitar, et al.
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res., September 1, 2006; 12(17): 5165 - 5173.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
J. Clin. Oncol., August 20, 2006; 24(24): 3904 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Langebrake, U. Creutzig, M. Dworzak, O. Hrusak, E. Mejstrikova, F. Griesinger, M. Zimmermann, and D. Reinhardt
Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group
J. Clin. Oncol., August 1, 2006; 24(22): 3686 - 3692.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al.
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
Blood, July 15, 2006; 108(2): 685 - 696.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. S. Farag, K. J. Archer, K. Mrozek, A. S. Ruppert, A. J. Carroll, J. W. Vardiman, M. J. Pettenati, M. R. Baer, M. B. Qumsiyeh, P. R. Koduru, et al.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Blood, July 1, 2006; 108(1): 63 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. D. Gore, S. Baylin, E. Sugar, H. Carraway, C. B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J. E. Karp, et al.
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer Res., June 15, 2006; 66(12): 6361 - 6369.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Levine, A. Tulpule, D. I. Quinn, G. Gorospe III, D. L. Smith, L. Hornor, W. D. Boswell, B. M. Espina, S. G. Groshen, R. Masood, et al.
Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy
J. Clin. Oncol., April 10, 2006; 24(11): 1712 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M.-T. Krauth, S. Florian, A. Bohm, K. Sonneck, H. Agis, P. Samorapoompichit, A. W. Hauswirth, W. R. Sperr, and P. Valent
Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5
J. Immunol., February 1, 2006; 176(3): 1759 - 1768.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Oki, H. M. Kantarjian, X. Zhou, J. Cortes, S. Faderl, S. Verstovsek, S. O'Brien, C. Koller, M. Beran, B. N. Bekele, et al.
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
Blood, February 1, 2006; 107(3): 880 - 884.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, C. D. Baldus, A. S. Ruppert, M. D. Radmacher, K. Mrozek, S. P. Whitman, J. E. Kolitz, C. G. Edwards, J. W. Vardiman, B. L. Powell, et al.
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol., December 20, 2005; 23(36): 9234 - 9242.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. E. Gale, R. Hills, A. R. Pizzey, P. D. Kottaridis, D. Swirsky, A. F. Gilkes, E. Nugent, K. I. Mills, K. Wheatley, E. Solomon, et al.
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
Blood, December 1, 2005; 106(12): 3768 - 3776.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. van der Holt, B. Lowenberg, A. K. Burnett, W. U. Knauf, J. Shepherd, P. P. Piccaluga, G. J. Ossenkoppele, G. E. G. Verhoef, A. Ferrant, M. Crump, et al.
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Blood, October 15, 2005; 106(8): 2646 - 2654.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, K. Mrozek, A. S. Ruppert, K. Maharry, J. E. Kolitz, J. O. Moore, R. J. Mayer, M. J. Pettenati, B. L. Powell, C. G. Edwards, et al.
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study
J. Clin. Oncol., August 20, 2005; 23(24): 5705 - 5717.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C.-C. Chen, C.-F. Yang, M.-H. Yang, K.-D. Lee, W.-K. Kwang, J.-Y. You, Y.-B. Yu, C.-H. Ho, C.-H. Tzeng, W.-K. Chau, et al.
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia
Ann. Onc., August 1, 2005; 16(8): 1366 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Testi, A. Biondi, F. L. Coco, M. L. Moleti, F. Giona, M. Vignetti, G. Menna, F. Locatelli, A. Pession, E. Barisone, et al.
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children
Blood, July 15, 2005; 106(2): 447 - 453.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. K. Kelly, O. A. O'Connor, L. M. Krug, J. H. Chiao, M. Heaney, T. Curley, B. MacGregore-Cortelli, W. Tong, J. P. Secrist, L. Schwartz, et al.
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
J. Clin. Oncol., June 10, 2005; 23(17): 3923 - 3931.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, W. Stock, G. Dai, R. B. Klisovic, S. Liu, M. I. Klisovic, W. Blum, C. Kefauver, D. A. Sher, M. Green, et al.
Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity
J. Clin. Oncol., May 20, 2005; 23(15): 3404 - 3411.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. O. Moore, S. L. George, R. K. Dodge, P. C. Amrein, B. L. Powell, J. E. Kolitz, M. R. Baer, F. R. Davey, C. D. Bloomfield, R. A. Larson, et al.
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Blood, May 1, 2005; 105(9): 3420 - 3427.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood, February 1, 2005; 105(3): 959 - 967.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A.-M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, et al.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
Blood, February 1, 2005; 105(3): 986 - 993.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Farag, A. S. Ruppert, K. Mrozek, R. J. Mayer, R. M. Stone, A. J. Carroll, B. L. Powell, J. O. Moore, M. J. Pettenati, P. R.K. Koduru, et al.
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol., January 20, 2005; 23(3): 482 - 493.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Kolitz, S. L. George, R. K. Dodge, D. D. Hurd, B. L. Powell, S. L. Allen, E. Velez-Garcia, J. O. Moore, T. C. Shea, E. Hoke, et al.
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
J. Clin. Oncol., November 1, 2004; 22(21): 4290 - 4301.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Creutzig, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and T. Lehrnbecher
Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98
J. Clin. Oncol., November 1, 2004; 22(21): 4384 - 4393.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Castaigne, S. Chevret, E. Archimbaud, P. Fenaux, D. Bordessoule, H. Tilly, T. de Revel, M. Simon, B. Dupriez, M. Renoux, et al.
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study
Blood, October 15, 2004; 104(8): 2467 - 2474.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Creutzig and G.J.L. Kaspers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol., August 15, 2004; 22(16): 3432 - 3433.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. Nabhan, L. Rundhaugen, M. Jatoi, M. B. Riley, L. Boehlke, L. C. Peterson, and M. S. Tallman
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease
Ann. Onc., August 1, 2004; 15(8): 1231 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. H. Min, J.-W. Cheong, J. Y. Kim, J. I. Eom, S. T. Lee, J. S. Hahn, Y. W. Ko, and M. H. Lee
Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia
Cancer Res., August 1, 2004; 64(15): 5225 - 5231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. H. Min, J.-W. Cheong, M. H. Lee, J. Y. Kim, S. T. Lee, J. S. Hahn, and Y. W. Ko
Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia: Its Association with Constitutive Phosphorylation of Phosphatase and Tensin Homologue Protein and Poor Prognosis
Clin. Cancer Res., August 1, 2004; 10(15): 5123 - 5130.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, K. Mrozek, A. S. Ruppert, K. J. Archer, M. J. Pettenati, N. A. Heerema, A. J. Carroll, P. R.K. Koduru, J. E. Kolitz, L. J. Sterling, et al.
Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461
J. Clin. Oncol., June 15, 2004; 22(12): 2410 - 2418.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al.
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab
Clin. Cancer Res., June 1, 2004; 10(11): 3577 - 3585.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Sekeres, B. Peterson, R. K. Dodge, R. J. Mayer, J. O. Moore, E. J. Lee, J. Kolitz, M. R. Baer, C. A. Schiffer, A. J. Carroll, et al.
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia
Blood, June 1, 2004; 103(11): 4036 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. C. Byrd, A. S. Ruppert, K. Mrozek, A. J. Carroll, C. G. Edwards, D. C. Arthur, M. J. Pettenati, J. Stamberg, P. R.K. Koduru, J. O. Moore, et al.
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461
J. Clin. Oncol., March 15, 2004; 22(6): 1087 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, R. F. Schlenk, I. Stolze, J. Bihlmayr, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
J. Clin. Oncol., February 15, 2004; 22(4): 624 - 633.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Sanz, G. Martin, M. Gonzalez, A. Leon, C. Rayon, C. Rivas, D. Colomer, E. Amutio, F. J. Capote, G. A. Milone, et al.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group
Blood, February 15, 2004; 103(4): 1237 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Buchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, et al.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol., December 15, 2003; 21(24): 4642 - 4649.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Tur, M. Huhn, T. Thepen, M. Stocker, R. Krohn, S. Vogel, E. Jost, R. Osieka, J. G. van de Winkel, R. Fischer, et al.
Recombinant CD64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells
Cancer Res., December 1, 2003; 63(23): 8414 - 8419.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. H. Estey, P. F. Thall, X. Wang, S. Verstovsek, J. Cortes, and H. M. Kantarjian
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML
Blood, November 1, 2003; 102(9): 3097 - 3099.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Fiedler, R. Mesters, H. Tinnefeld, S. Loges, P. Staib, U. Duhrsen, M. Flasshove, O. G. Ottmann, W. Jung, F. Cavalli, et al.
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Blood, October 15, 2003; 102(8): 2763 - 2767.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Zwaan, S. Meshinchi, J. P. Radich, A. J. P. Veerman, D. R. Huismans, L. Munske, M. Podleschny, K. Hahlen, R. Pieters, M. Zimmermann, et al.
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
Blood, October 1, 2003; 102(7): 2387 - 2394.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. D. Baldus, S. M. Tanner, A. S. Ruppert, S. P. Whitman, K. J. Archer, G. Marcucci, M. A. Caligiuri, A. J. Carroll, J. W. Vardiman, B. L. Powell, et al.
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
Blood, September 1, 2003; 102(5): 1613 - 1618.
[Abstract]